Active Ingredient(s): Anifrolumab-fnia
FDA Approved: * July 30, 2021
Pharm Company: * ASTRAZENECA AB
Category: Immune System

Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE).[1][2] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.[medical citation needed] Anifrolumab was approved for medical use in the United States in August 2021.[1][3][4][5... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Saphnelo 300 mg/2ml Intravenous Injection, Solution
NDC: 0310-3040
Astrazeneca Pharmaceuticals Lp